First Risperdal Philadelphia Trial Verdict of $2.5 Million

The verdict over the antipsychotic drug Risperdal’s connection to abnormal breast tissue growth in males has returned $2.5 million in damages against a Johnson & Johnson unit, Janssen Pharmaceuticals Inc.

This verdict came after a lengthy trial in the Philadelphia County Court of Common Pleas when the jury found that Johnson & Johnson failed to warn the parents and physicians of an autistic boy about the risks associated with the drug.

According to the evidence presented, Janssen Pharmaceuticals Inc. concealed facts that the drug was linked to a condition known as gynecomastia, which causes adolescent boys to grow female breast tissue.

This is the first Philadelphia verdict to come of the thousands of product liability lawsuits over Risperdal’s links to gynecomastia that are pending throughout the nation. As part of a mass tort docket in Philadelphia, over 1,250 cases are currently lined up involving the drug Risperdal.

In this particular case, Janssen has been accused of manipulating scientific data to represent that Risperdal has had less of a negative effect on adolescent children using the drug for treatment. The company has previously admitted to criminal misconduct, paying $2.2 billion to resolve federal False Claims Act allegations back in 2013 for illegally promoting three of its drugs for off label use, including Risperdal.

If you or your child has been prescribed Risperdal and has suffered medical complications, contact Caputo and Mariotti today to find out what you can do to protect your rights.

Share